High BMI is a modifiable risk factor for end-stage renal disease

2006 ◽  
Vol 2 (4) ◽  
pp. 180-181
Author(s):  
Rachael Williams
Keyword(s):  
Risk Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Modifiable Risk Factor ◽  
Stage Renal Disease ◽  
End Stage ◽  
High Bmi

scholarly journals Is Frailty a Modifiable Risk Factor of Future Adverse Outcomes in Elderly Patients with Incident End-Stage Renal Disease?

2017 ◽  
Vol 32 (11) ◽  
pp. 1800 ◽  
Author(s):  
Sung Woo Lee ◽  
Anna Lee ◽  
Mi-Yeon Yu ◽  
Sun-wook Kim ◽  
Kwang-il Kim ◽  
...  
Keyword(s):  
Risk Factor ◽  
Elderly Patients ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Adverse Outcomes ◽  
Modifiable Risk Factor ◽  
Stage Renal Disease ◽  
End Stage

Abstract 282: In Hospital Outcomes of Cardiac Arrest in Patient with End Stage Renal Disease

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_4) ◽  
Author(s):  
Muhammad Khan ◽  
Muhammad U Khan ◽  
Muhammad Munir
Keyword(s):  
Cardiac Arrest ◽  
Risk Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
International Classification ◽  
International Classification Of Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: End stage renal disease (ESRD) is a well-recognized risk factor for development of sudden cardiac arrest(SCA). There is limited data on outcomes after an in-hospital SCA event in ESRD patients. Methods: Data were obtained from National Inpatient Sample from January 2007 to December 2017. In-hospital SCA was identified using International Classification of Disease, 9th Revision, Clinical Modification, and International Classification of Disease, 10th Revision, Clinical Modification codes of 99.60, 99.63, and 5A12012. ESRD patients were subsequently identified using codes of 585.6 and N18.6. Propensity -matched analysis using logistic regression with SD caliper of 0.2 was used to match patients with and without ESRD. Crude and propensity-matched (PS) cohorts outcomes were calculated. Results: A total of 1,412,985 patients sustained in-hospital SCA during our study period. ESRD patients with in-hospital SCA were younger and had a higher burden of key co-morbidities. Mortality was similar in ESRD and non-ESRD patients in PS matched cohort (70.4% vs. 70.7%, p = 0.45, figure 1) with an overall downward trend over our study years (figure 2). Conclusion: In the context of in-hospital SCA, mortality is similar in ESRD and non-ESRD patients in adjusted analysis. Adequate risk factor modification could further mitigate the risk of in-hospital SCA among ESRD patients

Nocturnal Hypoxemia: A Neglected Cardiovascular Risk Factor in End-Stage Renal Disease?

2002 ◽  
Vol 20 (1) ◽  
pp. 120-123 ◽  
Author(s):  
Carmine Zoccali ◽  
Francesca Mallamaci ◽  
Giovanni Tripepi
Keyword(s):  
Risk Factor ◽  
Cardiovascular Risk ◽  
Renal Disease ◽  
Cardiovascular Risk Factor ◽  
End Stage Renal Disease ◽  
Nocturnal Hypoxemia ◽  
Stage Renal Disease ◽  
End Stage

Assessing Plasma Total Homocysteine in Patients with End-Stage Renal Disease

2007 ◽  
Vol 27 (5) ◽  
pp. 476-488 ◽  
Author(s):  
Bradley L. Urquhart ◽  
Andrew A. House
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Elevated Plasma ◽  
Plasma Thcy ◽  
Total Homocysteine ◽  
Stage Renal Disease ◽  
End Stage ◽  
Plasma Total Homocysteine

Elevated plasma total homocysteine (tHcy) is a risk factor for cardiovascular disease; however, in light of several recent randomized trials, the issue of causality has been cast into doubt. Patients with end-stage renal disease are particularly interesting as they consistently have elevated tHcy and their leading causes of morbidity and mortality are related to cardiovascular disease. In the present article, we review the early evidence for the homocysteine theory of atherosclerosis, homocysteine metabolism, mechanisms of toxicity, and pertinent available clinical investigations. Where appropriate, the sparse evidence of homocysteine in peritoneal dialysis is reviewed. We conclude by addressing the difficulties associated with lowering plasma tHcy in patients with end-stage renal disease and suggest some novel methods for lowering tHcy in this resistant population. Finally, to address the issue of causality, we recommend that clinicians and scientists await the results of the FAVORIT trial before abandoning homocysteine as a modifiable risk factor for cardiovascular disease, as this study has recruited patients from a population with consistently elevated plasma tHcy who are known to respond to vitamin therapy.

Recreational drug use: A neglected risk factor for end-stage renal disease

2001 ◽  
Vol 38 (1) ◽  
pp. 49-56 ◽  
Author(s):  
Thomas V. Perneger ◽  
Michael J. Klag ◽  
Paul K. Whelton
Keyword(s):  
Risk Factor ◽  
Drug Use ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Recreational Drug ◽  
Recreational Drug Use ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Asymmetric Dimethylarginine: A Novel Cardiovascular Risk Factor in End-Stage Renal Disease

2012 ◽  
Vol 40 (1) ◽  
pp. 340-349 ◽  
Author(s):  
M Yusuf Alsagaff ◽  
M Thaha ◽  
M Aminuddin ◽  
RM Yogiarto ◽  
M Yogiantoro ◽  
...  
Keyword(s):  
Risk Factor ◽  
Cardiovascular Risk ◽  
Renal Disease ◽  
Cardiovascular Risk Factor ◽  
End Stage Renal Disease ◽  
Asymmetric Dimethylarginine ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document